The Technical Analyst
Ikena Oncology, Inc. [IKNA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ikena Oncology, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.44% $1.290
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 62.25 mill |
| EPS: | -1.630 |
| P/E: | -0.790 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 48.26 mill |
| Avg Daily Volume: | 0.433 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.790 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -0.790 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0436 (-96.62%) $-1.246 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.178 - 1.402 ( +/- 8.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Germa Caroline | Buy | 579 100 | Stock Option (Right to Buy) |
| 2024-02-29 | Germa Caroline | Buy | 0 | |
| 2024-02-01 | Ecsedy Jeffrey | Buy | 100 000 | Stock Option (Right to Buy) |
| 2024-02-01 | Marango Jotin | Buy | 181 000 | Stock Option (Right to Buy) |
| 2024-02-01 | Manfredi Mark | Buy | 320 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 95.73 |
| Last 94 transactions |
| Buy: 20 809 745 | Sell: 873 348 |
Forecast:
16:00 - $1.300
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.300
Forecast 2: 16:00 - $1.300
Forecast 3: 16:00 - $1.300
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.290 (-4.44% ) |
| Volume | 0.152 mill |
| Avg. Vol. | 0.433 mill |
| % of Avg. Vol | 35.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IKNA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IKNA
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-10 08:00:00 - Press Release
Ikena Oncology To Present At The Stifel 2024 Virtual Targeted Oncology Forum
Boston, april 10, 2024 (globe newswire) -- ikena oncology, inc. (nasdaq: ikna, “ikena,” “company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the stifel 2024 targeted oncology forum, taking place virtually from april 16-17, 2024. the company will also be holding one-on-one investor meetings at the event.
2024-03-12 08:00:00 - Press Release
Ikena Oncology Reports Fourth Quarter And Full Year 2023 Financial Results
Ik-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics ik-930 clinical update planned for 2h 2024 including additional data from ehe patients in dose escalation and initial mesothelioma patient data ik-595 phase i dose escalation study currently recruiting targeted patients closed 2023 in a strong financial position with $175m; runway into 2h 2026 boston, march 12, 2024 (globe newswire) -- ikena oncology, inc. (nasdaq: ikna, “ikena,” “company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending december 31, 2023. the company also provided an update across the organization and pipeline.
2024-02-27 08:00:00 - Press Release
Ikena Oncology To Participate In Td Cowen 44th Annual Health Care Conference
Boston, feb. 27, 2024 (globe newswire) -- ikena oncology, inc. (nasdaq: ikna, “ikena,” “company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the td cowen 44th annual health care conference, taking place march 4-6, 2024, in boston, ma. the company will also be holding one-on-one investor meetings at the conference.
2024-02-21 16:15:00 - Press Release
Ikena Oncology Appoints Caroline Germa, M.d. As Chief Medical Officer
Caroline germa, m.d., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
2024-01-18 16:05:00 - Press Release
Ikena Oncology Outlines Key Priorities And Provides Corporate Updates
Ik-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2h 2024 ik-595 first cohort treated and cleared safety evaluation window focused execution on core targeted oncology clinical programs; organizational reallocation of resources from exploratory discovery to clinical development of ik-930 and ik-595 ended 2023 in strong financial position with approximately $175 million in cash; runway extended into 2h 2026 boston, jan. 18, 2024 (globe newswire) -- ikena oncology, inc. (nasdaq: ikna, “ikena,” “company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, ik-930 and ik-595...
Latest News
2024-04-10 08:00:00 - GlobeNewsWire
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event.
2024-01-24 10:36:06 - Zacks Investment Research
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-06-20 10:16:40 - Zacks Investment Research
Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2023-06-02 09:53:37 - Zacks Investment Research
Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2023-05-24 08:00:00 - GlobeNewsWire
Ikena Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in TD Cowen's 4th Annual Oncology Innovation Summit taking place May 30-31, 2023, and the Jefferies Healthcare Conference taking place June 7-9, 2023.
2023-05-15 10:41:31 - Zacks Investment Research
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.47 per share a year ago.
2023-05-05 03:50:04 - Zacks Investment Research
Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?
Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2023-03-14 09:58:19 - Zacks Investment Research
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-07 11:30:02 - Zacks Investment Research
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-05 08:05:00 - GlobeNewsWire
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022.